A Study of HLX42 in Advanced/Metastatic Solid Tumors

This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.

Trial Details

NCT ID
NCT06210815
Phase
PHASE1
Sponsor
Shanghai Henlius Biotech
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HLX42
Locations (sample)
  • Guangdong, Guangzhou, China|42.76832,129.33635

Key Eligibility Criteria

  • ≥ 18 years and ≤ 75 years at the time of signing the ICF, male or female;
  • Patients with histologically or cytologically confirmed advanced/metastatic malignant solid tumors, who are refractory to or intolerable with stand…
  • At least one measurable lesion as per RECIST 1.1；
  • An ECOG performance status score of 0-1；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →